September 13, 2017 – Local communities and families are standing up against pharmaceutical companies for misleading patients about the dangerous effects of opioids.
According to philly.com, the U.S. Senate held a hearing about the marketing practices of the pharmaceutical industry.
Deborah Fuller, of Cherry Hill, shared her thoughts that Insys Therapeutics Inc. contributed to the overdose death of her daughter, 32-year-old Sarah Fuller.
Malvern Treatment Centers operates an outpatient center in Cherry Hill, located at 401 Kings Highway, Building #1.
Her mother, Deborah, described listening to an audio recording in which a drug company representative falsely said she was from Sarah’s doctor’s office and misled a pharmacy benefits manager into believing that Sarah had breakthrough cancer pain. That’s the only condition that Insys’ fast-acting fentanyl brand, Subsys, was approved to treat.
“Every day of my life, I must live with the realization that Sarah is gone because of Insys’ greed,” Fuller said. “I believe that Sarah’s death certificate should be changed to indicate her death was a homicide and the cause of death should be changed to ‘corporate greed.’”
Read the full story on philly.com.